ArticleJournal of current ophthalmology
Mesenchymal Stem Cell-Derived Exosomes for Keratoconus: A Novel Therapeutic Approach.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconus (KC) is a progressive corneal ectatic disorder with limited treatment options addressing its underlying pathophysiology. Current therapies, including corneal cross-linking and transplantation, focus on halting progression rather than reversing damage. Mesenchymal stem cell-derived exosomes (MSC-Exo) have emerged as promising cell-free therapeutic agents with regenerative, anti-inflammatory, and immunomodulatory properties. This short communication synthesizes current evidence on MSC-Exo for KC treatment. Preclinical studies demonstrate that MSC-Exo enhances keratocyte proliferation, reduces fibrosis and inflammation, modulates extracellular matrix proteins, and promotes epithelial wound healing. Exosomes from various MSC sources show therapeutic efficacy across
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.